Ocular toxicities of fibroblast growth factor receptor inhibitors: A review.

Jerry Hsu, Jasmine H Francis, Sumayya Ahmad

Journal: Survey of ophthalmology 2023;69(1):34-41

PMID: 37777119

Full Text on Elsevier Science View on PubMed

Abstract

Fibroblast growth factor receptor (FGFR) inhibitors are an emerging class of small molecule targeted cancer drugs with promising therapeutic possibilities for a wide variety of malignancies. While ocular adverse events from FGFR inhibitors are reported in clinical trials, subsequent case studies continue to reveal new toxicities. Disease pathology affecting multiple parts of the eye has been reported, but the ocular surface and the retina are the most commonly encountered areas affected by FGFR inhibitors, manifesting as dry eye and FGFR inhibitor-associated retinopathy, respectively. Corneal thinning and melt is a rare but serious and potentially vision-threatening complication of FGFR inhibitor toxicity. Similarities between toxicities observed from other targeted cancer therapy drugs and FGFR inhibitors may help us understand underlying pathophysiological changes. The management of these adverse events requires close ophthalmologic follow-up and may require discontinuation of the offending agents in some cases.

Address: New York Eye and Ear Infirmary of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Ophthalmology, Weill-Cornell Medical Center, New York, NY, USA.; New York Eye and Ear Infirmary of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: [email protected].

DOI: 10.1016/j.survophthal.2023.09.007

Link outs

Free resources

Medical:

https://medlineplus.gov/eyediseases.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Receptors, Fibroblast Growth Factor, Antineoplastic Agents, Protein Kinase Inhibitors, Eye Diseases